Morphine suppresses the alloantigen-driven CTL response in a dose-dependent and naltrexone reversible manner

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 2, 1996, Pages 980-988

  Scott, Mace ^a   Carr, Daniel J J ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD8 ANTIGEN; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MORPHINE; NALTREXONE;

ALLOIMMUNIZATION; ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOANTIGENS; LYMPHOCYTES; MICE; MICE, INBRED STRAINS; MORPHINE; NALTREXONE; RNA;

EID: 0030426850     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. BADDLEY, J. W., PAUL, D. AND CARR, D. J. J.: Acute morphine administration alters the expression of β-adrenergic receptors on splenic lymphocytes. Adv. Biosciences 86: 593-597, 1993.
2. BAKER, M. L., BROCKUNIER, L. L., BAGLEY, J. R., FRANCE, C. P. AND CARR, D. J. J.: Fentanyl-related 4-heteroanilido piperidine OHM3295 augments splenic natural killer activity and induces analgesia through opioid receptor pathways. J. Pharmacol. Exp. Ther. 274: 1285-1292, 1995.
3. BASS, W. B. AND VANDERBROOK, M. J.: A note on an improved method of analgesic evaluation. J. Am. Pharm. Assoc. 41: 569-570, 1952.
4. BAYER, B. M., DAUSSIN, S., HERNANDEZ, M. AND IRVIN, L.: Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 29: 369-374, 1990.
5. BELKOWSKI, S. M., ZHU, J., LIU-CHEN, L. Y., EISENSTEIN, T. K., ADLER, M. W., ROGERS, T. J.: Sequence of κ-opioid receptor cDNA in the R1.1 thymoma cell line. J. Neuroimmunol. 62: 113-117, 1995.
6. BERKE, G.: The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects. Annu. Rev. Immunol. 12: 735-773, 1994.
7. BERKE, G.: Unlocking the secrets of CTL and NK cells. Immunol. Today 16: 343-346, 1996.
8. BRYANT, H. U., BEMTON, E. W. AND HOLADAY, J. W.: Immunosuppressive effects of chronic morphine treatment in mice. Life Sci. 41: 1731-1738, 1987.
9. BUSSIERE, J. L., ADLER, M. W-, ROGERS, T. J. AND EISENSTEIN, T. K.: Cytokine reversal of morphine-induced suppression of the antibody response. J. Pharmacol. Exp. Ther. 264: 591-597, 1993.
10. CARPENTER, G. W., BREEDEN, L. AND CARR, D. J. J.: Acute exposure to morphine suppresses CTL activity. Int. J. Immunopharmacol. 17: 1001-1006, 1995.
11. CARPENTER, G. W., GARZA, H. H. JR., GEBHARDT, B. M. AND CARR, D. J. J.: Chronic morphine treatment suppresses CTL-mediated cytolysis, granulation, and cAMP responses to alloantigen. Brain Behavior Immun. 8: 185-203, 1994.
12. CARR, D. J. J., BROCKUNIER, L. L., SCOTT, M., BAGLEY, J. R. AND FRANCE, C. P.: Mirfentanil antagonizes morphine-induced suppression of splenic NK activity in mice. Immunopharmacology, in press, 1996.
13. CARR, D. J. J. AND FRANCE, C. P.: Immune alterations in morphine-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 267: 9-15, 1993.
14. CARR, D. J. J., GEBHARDT, B. M. AND PAUL, D.: Alpha adrenergic and mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity. J. Pharmacol. Exp. Ther. 264: 1179-1186, 1993.
15. CARR, D. J. J., GERAK, L. R. AND FRANCE, C. P.: Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice. J. Pharmacol. Exp. Ther. 269: 693-698, 1994.
16. CHUANG, L. F., CHUANG, T. K., KILLAM, K. F. JR., CHUANG, A. J., KUNG, H.-F., YU, L. AND CHUANG, R. Y.: Delta opioid receptor gene expression in lymphocytes. Biochem. Biophys. Res. Commun. 202: 1291-1299, 1994.
17. CHUANG, T. K., KILLAM, K. F. JR., CHUANG, L. F., KUNG, H-F., SHENG, W. S., CHAO, C. C., YU, L. AND CHUANG, R. Y.: Mu opioid receptor gene expression in immune cells. Biochem. Biophys. Res. Commun. 216: 922-930, 1995.
18. CURRAN, J. W., JAFFE, H. W., HARDY, A. M., MORGAN, W. M., SELIK, R. M. AND DONDERO, T. J.: Epidemiology of HIV infection and AIDS in the United States. Science (Wash. DC) 239: 610-616, 1988.
19. D'AMOUR, F. E. AND SMITH, D. L.: A method for determining loss of pain sensation, J. Pharmacol. Exp. Ther. 72: 74-79, 1941.
20. DONAHOE, R. M., BUESCO-RAMOS, C., FALEK, A., MCCLURE, H. AND NICHOLSON, J. K. A.: Comparative effects of morphine on leukocytic antigenic markers of monkeys and humans. J. Neurosci. Res. 19: 157-165, 1988.
21. FARRAR, M. A. AND SCHREIBER, R. D.: The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol. 11: 571-611, 1993.
22. FECHO, K., DYKSTRA, L. A. AND LYSIE, D. T.: Evidence for beta adrenergic receptor involvement in the immunomodulatory effects of morphine. J. Pharmacol. Exp. Ther. 265: 1079-1087, 1993.
23. FELTEN, D. L., FELTEN, S. Y., CARLSON, S. Y., OLSCHOWKA, J. A. AND LIVNAT, S.: Noradrenergic and peptidergic innervation of lymphoid tissue. J. Immunol. 135: 755s-765s, 1985.
24. FREIER, D. O. AND FUCHS, B. A.: Morphine-induced alterations in thymocyte subpopulations of B6C3F1 mice. J. Pharmacol. Exp. Ther. 265: 81-88, 1993.
25. HANNA, N. AND BURTON, R. C.: Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J. Immunol. 127: 1754-1758, 1981.
26. HANSSON, M., KARRE, K., KIESSLING, R., RODER, J., ANDERSSON, B. AND HAYRY, P.: Natural NK-cell targets in the mouse thymus: Characteristics of the sensitive cell population. J. Immunol. 123: 765-771, 1979.
27. HERBERMAN, R. B. AND HOLDEN, H. T.: Natural cell-mediated immunity. Adv. Cancer Res. 27: 305-377, 1978.
28. HERBERMAN, R. B. AND ORTALDO, J. R.: Natural killer cells: Their role in defenses against disease. Science (Wash DC) 214: 24-30, 1981.
29. HOFFMAN, R. W., BLUESTONE, J. A., LEO, O. AND SHAW, S.: Lysis of anti-T3-bearing murine hybridoma cells by human allospecific cytotoxic T cell clones and inhibition of that lysis by anti-T3 and anti-LFA-1 antibodies. J. Immunol. 135: 5-8, 1985.
30. HUNG, C. Y., LEFKOWITZ, S. S. AND GEBER, W. F.: Interferon inhibition by narcotic analgesics. Proc. Soc. Exp. Biol. Med. 142: 106-111, 1973.
31. KIMES, A. S., SMITH, W. J., WINCHELL, C. J. AND LONDON, E. D.: Effects of morphine on the phenotypic expression of cell surface markers on murine lymphocytes. Life Sci. 51: 807-815, 1992.
32. LANDOLFO, S., COFANO, F., BIOVARELLI, M., PRAT, M., CAVALLO, G. AND FORNI, G.: Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science (Wash DC) 229: 176-179, 1985.
33. LEVY, S. M., FERNSTHOM, J., HERBERMAN, R. B., WHITESIDE, T., LEE, J., WARD, M. AND MASSOUDI, M.: Persistently low natural killer cell activity and circulating levels of plasma beta endorphin: Risk factors for infectious disease. Life Sci. 48: 107-116, 1991.
34. LIU, Y., BLACKBOURN, J., CHUANG, L. F., KILLAM, K. F. JR. AND CHUANG, R. Y.: Effects of in vivo and in vitro administration of morphine sulfate upon rhesus macaque polymorphonuclear cell phagocytosis and chemotaxis. J. Pharmacol. Exp. Ther. 263: 533-539, 1992.
35. LYSLE, D. T., COUSSONS, M. E., WATTS, V. J., BENNETT, E. H. AND DYKSTRA, L. A.: Morphine-induced alterations of immune status: Dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265: 1071-1078, 1993.
36. MAITY, R., MUKHERJEE, R. AND SKOLNICK, P.: Morphine inhibits the development of allogeneic immune responses in mouse lymph node. Immunopharmacology 29: 175-183, 1995.
37. MATHEWS, P. M., FROELICH, C. J., SIBBITT, W. L. AND BANKHURST, A. D.: Enhancement of natural cytotoxicity by β-endorphin. J. Immunol. 130: 1658-1662, 1983.
38. MCCHESNEY, M. B. AND OLDSTONE, M. B.: Viruses perturb lymphocyte functions: Selected principles characterizing virus-induced immunosuppression. Annu. Rev. Immunol. 5: 279-304, 1987.
39. MOLITOR, T. W., MORILIA, A., RISDAHL, J. M., MURTAUGH, M. P., CHAO, C. C. AND PETERSON, P. K.: Chronic morphine administration impairs cell-mediated immune responses in swine. J. Pharmacol. Exp. Ther. 260: 581-586, 1992.
40. MOZZANICA, N., FINZI, A. F., FOPPA, S., VIGNATI, G. AND VILLA, M. L.: Association between circadian rhythms of endogenous hypothalamic opioid peptides and of natural killer cell activity. Int. J. Immunopharmacol. 13: 317-321, 1991.
41. NANDI, D., JIANG, H. AND MONACO, J. J.: Identification of MECL-1 (LMP-10) as the third IFN-γ-inducible proteasome subunit. J. Immunol. 156: 2361-2364, 1996.
42. NOVICK, D. M., OCHSHORN, M., GHALI, V., CROXSON, T. S., MERCER, W-D., CHIORAZZI, N. AND KREEK, M. J.: Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 250: 606-610, 1989.
43. SAMBROOK, J., FRISCH, E. F., MANIATIS, T.: Molecular cloning: A laboratory manual. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982.
44. SHAVIT, Y., LEWIS, J. W., TERMAN, G. W., GALE, R. P. AND LIEBESKIND, J. C.: Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science (Wash DC) 223: 188-190, 1984.
45. TRINCHIERI, G.: Biology of natural killer cells. Adv. Immunol. 47: 187-376, 1989.
46. ZINKERNAGEL, R. M. AND DOHERTY, P. C.: H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded in H2K or H-2D. J. Exp. Med. 141: 1427-1436, 1975.